Global Adalimumab Biosimilar Market

Report ID : 1058 | Published : 2022-08-16 | Pages: 140 | Format: PDF/EXCEL

Adalimumab is a first humanized monoclonal antibody indicated for the treatment of various autoimmune diseases. Adalimumab is an anti-TNF (tumour necrosis factor) drug that block the action of TNF (tumour necrosis factor) to reduce the inflammation. It is prescribed for the treatment of diseases such as rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and psoriasis. It was first discovered by “phage display” technique which was named ‘D2E7’. Furthermore, it experienced the various manufacturing process at BASF Bioresearch Corporation and developed by BASF Knoll. In December 2000, Abbott announced the acquisition of BASF Bioresearch Corporation. In January 2013, Abbott Laboratories separated its pharma business named as AbbVie Inc. which was further involved in development and commercializing activities. AbbVie marketed Adalimumab product under the trade name of Humira. It was approved by U.S. Food Drug and Administration (FDA) in 2008 and by European Medicines Agency in 2003. However, the patent on Humira has expired in Europe in June 2017 and in the U.S. in November 2017. It is world’s best-selling drug thus several pharmaceutical companies are focusing on the development of biosimilar adalimumab products. Some of the market players leading the global adalimumab biosimilar market include Amgen, Pfizer, Sandoz International GmbH, Celltrion Healthcare Co., Ltd., Fresenius Kabi, Kyowa Hakko Kirin, LG Life Sciences, Mochida Pharmaceutical, and Momenta Pharmaceuticals.

The adalimumab biosimilar market is expected to grow at rapid pace during forecast period. Adalimumab is world’s one of the top best-selling drug. Moreover, entry of adalimumab biosimilar players into market is expected to boost the growth of global adalimumab biosimilar market. For instance, in 2017, U.S. FDA approved Boehringer Ingelheim’s ‘Cyltezo’ adalimumab biosimilar drug for multiple indications. In addition, the factors s presence of such as presence of strong pipeline molecules such as FKB-327, GP-2017, Amgevita, and many more along with rising incidence of autoimmune disorders (such rheumatoid arthritis) is expected to compel the demand for adalimumab biosimilar market. Growing demand for biosimilar drugs and increase in demand for cost effective treatment in low and medium income countries further drives the growth of the adalimumab biosimilar market during the forecast period. However, stringent regulatory process for the approval of biosimilar is major restraining factor that hampers the growth of the adalimumab biosimilar market. Also, strategies used by the patent holder companies to fight against the biosimilar competition hampers the growth of the adalimumab biosimilar market. For instance, Abbvie filed a complaint against Boehringer Ingelheim for a biosimilar version Humira.

Based on application, the global adalimumab biosimilar market is segmented in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, Crohn’s disease, ankylosing spondylitis, ulcerative colitis, and psoriasis. Rheumatoid arthritis application segment is expected to grow at higher pace during the forecast period owing to increasing incidence and prevalence rate of disease across the globe. Based on distribution channel the global adalimumab biosimilar market is segmented as hospital pharmacy, online pharmacy and other direct distribution channels. Online pharmacy segment is expected to grow during forecast period due to rapidly increasing adoption of online pharmacy portals to buy the drugs.

At regional level, the global adalimumab biosimilar market has been segmented into Asia Pacific, Europe, North America, Latin America and Middle East & Africa. In terms of revenue, Europe is major contributor for the global adalimumab biosimilar market. This is attributed owing to the factor such as less stringent regulatory product approval process compared to US FDA and high demand for biosimilar drugs. Europe is followed by North America which is second major revenue generator owing to factors such as strong pipeline product portfolio, rising focus on research and drug development activities. Asia Pacific is third promising region in terms of revenue contribution which is expected to grow at rapid pace in upcoming forecast period. Asian countries such as Japan, India and China are major contributors for Asia Pacific adalimumab biosimilar market. Presence emerging economies with rising healthcare expenditure and huge population base countries such as China and India offer tremendous opportunities

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Adalimumab Biosimilar Market Snapshot

Chapter 4. Global Adalimumab Biosimilar Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Applications Estimates & Trend Analysis

5.1. By Applications & Market Share, 2022 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 for the following By Applications:

5.2.1. Rheumatoid Arthritis

5.2.2. Juvenile Idiopathic Arthritis

5.2.3. Psoriatic Arthritis

5.2.4. Crohn’s Disease

5.2.5. Ankylosing Spondylitis

5.2.6. Ulcerative Colitis

5.2.7. Psoriasis

Chapter 6. Market Segmentation 2: By Distribution Channel Estimates & Trend Analysis

6.1. By Distribution Channel & Market Share, 2022& 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 for the following By Distribution Channel:

6.2.1. Hospital Pharmacy

6.2.2. Online Pharmacy

6.2.3. Retail Pharmacy

6.2.4. Other Direct Distribution Channels

Chapter 7. Adalimumab Biosimilar Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Applications, 2022 - 2030

7.1.2. North America Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2022 - 2030

7.1.3. North America Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts by country, 2022 - 2030

7.2. Europe

7.2.1. Europe Adalimumab Biosimilar Market revenue (US$ Million) By Applications, 2022 - 2030

7.2.2. Europe Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2022 - 2030

7.2.3. Europe Adalimumab Biosimilar Market revenue (US$ Million) by country, 2022 - 2030

7.3. Asia Pacific

7.3.1. Asia Pacific Adalimumab Biosimilar Market revenue (US$ Million) By Applications, 2022 - 2030

7.3.2. Asia Pacific Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2022 - 2030

7.3.3. Asia Pacific Adalimumab Biosimilar Market revenue (US$ Million) by country, 2022 - 2030

7.4. Latin America

7.4.1. Latin America Adalimumab Biosimilar Market revenue (US$ Million) By Applications, (US$ Million)

7.4.2. Latin America Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2022 - 2030

7.4.3. Latin America Adalimumab Biosimilar Market revenue (US$ Million) by country, (US$ Million) 2022 - 2030

7.5. Middle East & Africa

7.5.1. Middle East & Africa Adalimumab Biosimilar Market revenue (US$ Million) By Applications, (US$ Million)

7.5.2. Middle East & Africa Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2022 - 2030

7.5.3. Middle East & Africa Adalimumab Biosimilar Market revenue (US$ Million) by country, (US$ Million) 2022 - 2030

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. Amgen Inc.

8.2.2. Pfizer Inc.

8.2.3. Sandoz International GmbH

8.2.4. Celltrion Healthcare Co., Ltd.

8.2.5. Fresenius Kabi AG

8.2.6. Kyowa Hakko Kirin Co., Ltd.

8.2.7. LG Life Sciences Ltd.

8.2.8. Mochida Pharmaceutical Co., Ltd.

8.2.9. Momenta Pharmaceuticals, Inc.

8.2.10. Other Prominent Player

Global Adalimumab Biosimilar Market Segmentation

Global Adalimumab Biosimilar Market Outlook (Revenue, US$ Mn, 2019 – 2030) By Application

  • Rheumatoid Arthritis
  • Juvenile Idiopathic Arthritis
  • Psoriatic Arthritis
  • Crohn’s Disease
  • Ankylosing Spondylitis
  • Ulcerative Colitis
  • Psoriasis

Global Adalimumab Biosimilar Market Outlook (Revenue, US$ Mn, 2019 – 2030) By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Other Direct Distribution Channels

Global Adalimumab Biosimilar Market Outlook (Revenue, US$ Mn, 2019 – 2030) By Region

  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • India
    • China
    • Japan
    • South Korea
    • Australia & New Zealand
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

 

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Our Clients

Media Citations

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$3786
$10000
Get a Custom Report
Contact us with a specific research request.

Kindly share us with a topic or product segment or objectives to meet your strategy goals

Review Request

We’ll review your request & send a personalized quote for cost and time needed

Final Delivery

Sit back while our team work on your research. We will send bi-monthly updates and discuss our finding on a conference call upon final delivery..